ADC Therapeutics (ADCT) Cash from Investing Activities (2020 - 2026)
ADC Therapeutics (ADCT) posted quarterly Cash from Investing Activities of -$32000.0 for Q1 2026, up 87.88% year-on-year from -$17032.3 in Q1 2025, and down 104.86% on a QoQ basis from $659000.0 in Q4 2025.
ADC Therapeutics (ADCT) Cash from Investing Activities (2020 - 2026) Analysis & Trends
ADC Therapeutics (ADCT) has reported Cash from Investing Activities for 7 consecutive years, with -$32000.0 the latest figure, recorded in Q1 2026.
- Quarterly Cash from Investing Activities rose 87.88% year-over-year to -$32000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $627000.0 (up 204.5% YoY) and the FY2025 annual result came in at $395000.0, up 145.56% from the prior year.
- Cash from Investing Activities declined to -$32000.0 in Q1 2026 per ADCT's latest filing, from $659000.0 in the prior quarter.
- Over the last five years, Cash from Investing Activities for ADCT reached as high as $1.7 million in Q4 2022 and fell as low as -$1.4 million in Q1 2022.
- A 5-year average of -$293800.0 and a median of -$264000.0 in 2025 frame the typical range for Cash from Investing Activities.
- Annual changes were most pronounced in 2023 — Cash from Investing Activities slumped 160.24% — and 2025, when it jumped 832.22%.
- Year by year, Cash from Investing Activities stood at $1.7 million in 2022, then plunged by 119.19% to -$327000.0 in 2023, then surged by 72.48% to -$90000.0 in 2024, then soared by 832.22% to $659000.0 in 2025, then tumbled by 104.86% to -$32000.0 in 2026.
- According to Business Quant data, Cash from Investing Activities over the past three periods registered -$32000.0, $659000.0, and -$264000.0 for Q1 2026, Q4 2025, and Q1 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | -45.51 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | -431.90 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -428.90 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 172.62 Mn |
| 10 | ADC Therapeutics | 174.95 Mn | -56.06 Mn | 17.38 Mn | -32,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -32,000.00 |
| Mar 31, 2026 | -32,000.00 |
| Dec 31, 2025 | 659,000.00 |
| Dec 31, 2025 | 659,000.00 |
| Mar 31, 2025 | -264,000.00 |
| Mar 31, 2025 | -264,000.00 |
| Dec 31, 2024 | -90,000.00 |
| Dec 31, 2024 | -90,000.00 |
| Sep 30, 2024 | -216,000.00 |
| Sep 30, 2024 | -216,000.00 |
| Jun 30, 2024 | -30,000.00 |
| Jun 30, 2024 | -30,000.00 |
| Mar 31, 2024 | -531,000.00 |
| Mar 31, 2024 | -531,000.00 |
| Dec 31, 2023 | -327,000.00 |
| Dec 31, 2023 | -327,000.00 |
| Sep 30, 2023 | -661,000.00 |
| Sep 30, 2023 | -661,000.00 |
| Jun 30, 2023 | -1.21 Mn |
| Jun 30, 2023 | -1.21 Mn |